Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1986-7-14
|
pubmed:abstractText |
Thirty-three patients with various hematological malignancies were treated with Bestrabucil, the benzoate of an estradiol-chlorambucil conjugate, at doses of 50-300 mg daily p.o., consecutively. Nineteen patients had previously received chemotherapy. Of 29 evaluable patients, there were one CR and three PRs among 6 patients with chronic lymphocytic leukemia, two CRs and one PR among 4 patients with malignant lymphoma, two PRs among 3 patients with adult T-cell leukemia, one PR among 4 patients with macroglobulinemia, one PR for one patient with essential thrombocythemia, and one PR for a patient with chronic myelocytic leukemia. Main side effects included G1 symptoms (14%), estradiol-related symptoms (24%) and myelosuppression (32%).
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
13
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
2216-22
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3459398-Adult,
pubmed-meshheading:3459398-Aged,
pubmed-meshheading:3459398-Chlorambucil,
pubmed-meshheading:3459398-Drug Administration Schedule,
pubmed-meshheading:3459398-Drug Evaluation,
pubmed-meshheading:3459398-Estradiol,
pubmed-meshheading:3459398-Female,
pubmed-meshheading:3459398-Humans,
pubmed-meshheading:3459398-Leukemia, Lymphoid,
pubmed-meshheading:3459398-Leukemia, Myeloid,
pubmed-meshheading:3459398-Leukopenia,
pubmed-meshheading:3459398-Lymphoma,
pubmed-meshheading:3459398-Male,
pubmed-meshheading:3459398-Middle Aged,
pubmed-meshheading:3459398-Thrombocytopenia
|
pubmed:year |
1986
|
pubmed:articleTitle |
[Early phase II trial of bestrabucil in hematological malignancies].
|
pubmed:publicationType |
Journal Article,
English Abstract
|